Survival Factors and Metabolic Pathogenesis in Elderly Patients (≥65) With COVID-19: A Multi-Center Study

Qi Mei†, Amanda Y. Wang2,3,4†, Amy Bryant5†, Yang Yang6†, Ming Li7, Fei Wang6, Shangming Du8, Christian Kurts10, Patrick Wu11, Ke Ma12, Liang Wu13, Huawen Chen13, Jinlong Luo13, Yong Li14, Guangyuan Hu15†, Xianglin Yuan16† and Jian Li10*

† These authors have contributed equally to this work

Original Research

Background: Elderly patients infected with COVID-19 are reported to be facing a substantially increased risk of mortality. Clinical characteristics, treatment options, and potential survival factors remain under investigation. This study aimed to fill this gap and provide clinically relevant factors associated with survival of elderly patients with COVID-19.

Methods: In this multi-center study, elderly patients (age ≥65 years old) with laboratory-confirmed COVID-19 from 4 Wuhan hospitals were included. The clinical end point was hospital discharge or deceased with last date of follow-up on Jul. 08, 2020. Clinical, demographic, and laboratory data were collected. Univariate and multivariate analysis were performed to analyze survival and risk factors. A metabolic flux analysis using a large-scale molecular model was applied to investigate the pathogenesis of SARS-CoV-2 with regard to metabolism pathways.

Results: A total of 223 elderly patients infected with COVID-19 were included, 91 (40.8%) were discharged and 132 (59.2%) deceased. Acute respiratory distress syndrome (ARDS) developed in 140 (62.8%) patients, 23 (25.3%) of these patients survived. Multivariate analysis showed that potential risk factors for mortality were elevated D-Dimer (odds ratio: 1.13 [95% CI 1.04 - 1.22], p = 0.005), high immune-related metabolic index (6.42 [95% CI 2.66–15.48], p < 0.001), and increased neutrophil-to-lymphocyte ratio (1.08 [95% 1.03–1.13], p < 0.001). Elderly patients receiving interferon atmotherapy showed an increased probability of survival (0.29 [95% CI 0.17–0.51], p < 0.001). Based on these factors, an algorithm (AlgSurv) was developed to predict survival for elderly patients. The metabolic flux analysis showed that 12 metabolic
INTRODUCTION

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a non-segmented, single-stranded, and positive-sense RNA virus, recently discovered and categorized as the newest and seventh member of the Coronavirus family (1). Following the initial SARS-CoV-2 outbreak started in Dec. 2019 in Wuhan, China, the virus continues to cause a substantial number of casualties worldwide, with more than one million deaths and 35 million confirmed infections (2). The rapidly evolving situation and an increasing number of deaths has created a sense of urgency among scientists, leading to a large number of observational studies characterizing the clinical and epidemiological features of SARS-CoV-2 pneumonia and its spread (3–5). Several recent studies identified advanced age as a common potential risk factor associated with the course of the coronavirus disease 2019 (COVID-19) (6–9). More recently, changes of anatomical respiratory structure with aging (10), immunosenescence (11), and inflammaging (12) may represent three major determinants for a higher prevalence and mortality of COVID-19 infection in elderly populations. Further, age-related alterations in metabolism underlay changes in innate and adaptive immunity (13). However, the role of such metabolic alterations in the pathogenesis of SARS-CoV-2 remains under investigation.

This multi-center study investigated the clinical and epidemiological factors associated with survival in an age-specific (≥ 65 years at diagnosis) cohort and examine flux changes in metabolic pathways to better understand the role of viral metabolic host-dependency in the pathogenesis of SARS-CoV-2. Our findings provide evidence for key virus-host metabolic interactions involved in the pathogenesis in SARS-CoV-2 pneumonia in elderly patients. Such interactions could be targeted for newer vaccine and therapeutic development for these high-risk patients.

METHODS

Study Design

This retrospective and multi-center cohort study was conducted in 4 different hospitals in Wuhan: TJH, RHWU, WPH, and WNH (Figure 1). These 4 hospitals are government designated hospitals assigned to treat patients with SARS-CoV-2 pneumonia. Between January and March 2020, a total of 780 patients with laboratory-confirmed SARS-CoV-2 pneumonia were admitted to these 4 hospitals. The clinical end point for this study was life status (discharged or deceased) at the end of the observation period.

Patients

From the 780 SARS-CoV-2 pneumonia patients identified, 223 were recruited for this study. Of these, 101 were from TJH, 63 were from WPH, 38 were from WNH, and 21 were from RHWU. The inclusion criteria for study participants were [1] age ≥65 with confirmed diagnosis of SARS-CoV-2 pneumonia at one of the four study sites, [2] positive result of F137nCoV test for SARS-CoV-2 pneumonia, [3] CT-scan with clear evidence of viral pneumonia, [4] available data on the clinical outcome. The exclusion criteria were [1] age <65, [2] deceased within a day after hospital admission, [3] no related health records, [4] no data on clinical outcome, [5] suspected cases without positive result of F137nCoV test, or confirmed cases that were positive using a different test. All recruited participants provided informed consent. Data were recorded on the day of hospital admission in an electronic medical system, and were retrieved and sorted by professional medical staff. If missing values were found, a direct patient interview or telephone communication took place to attempt to obtain the missing information. None of this data has been published previously.

Treatment Protocol and Discharged Criteria for SARS-CoV-2 Pneumonia

The treatment protocols include either: [1] symptomatic treatment as a basis, active prevention of complications, treatment of underlying diseases, prevention of secondary infections, and timely support of organ vital function, or [2] oxygen-supply therapy including nasal catheter oxygen inhalation, oxygen-supply high nasal flow, invasive and non-invasive mechanical ventilation, or ECMO.

For interferon atmotherapy, patients received 5 × 10⁶ units of interferon α-2b (INFα-2b) nebulized in 4 ml of 0.9% saline with the following parameter: an air-flow rate of 3.0–6.0 L/min,
pressure of 90 k–120 kPa, an atomization rate of 350 ± 50 mg/min, and an equivalent volume particle size distribution of MMD: 4.2 ± 25%. Therapy was once daily over 20 min (14, 15) using a compression atomizer (model: BRM-075II).

The criteria for hospital discharge included: [1] stable and normal body temperature for > 3 days, [2] clear reduction in lung inflammation examined via CT-scan, [3] double negative results of the F137nCoV test with at least a 1 day interval, and [4] no comorbidity requiring transfer to another clinical department.

**Detection of SARS-CoV-2 With F137nCoV Test**

Upper respiratory tract samples from each patient were collected using nasopharyngeal and oropharyngeal swabs. Synthetic fiber swabs with plastic shafts were used to reduce any contamination risk. Subsequently RNA extraction (2–3 ml) from each sample was performed with a viral nucleic acid isolation kit (Roche). The RNA samples were then purified using QIAquick Gel Extraction Kit (Qiagen). The products were used for a real-time reverse transcription PCR (RT-PCR) assay (F137nCoV), which detected and matched the COVID-19 RNA. A positive result of F137nCoV was defined with Ct (cycle-count threshold)-value < 37 while a Ct-value ≥ 40 was deemed a negative result. A Ct-value between 37 and 40 required repeated testing (16).

**Estimation of Metabolic Flux and IM.Index**

For the calculation of IM.Index (immune-related metabolic index) of each patient, a large-scale model, MCPM, was applied (17). Laboratory values from each patient were applied as input to initialize the flux of corresponding metabolic reactions (Supplementary Figure 1):

\[
I_j \text{ (reaction, role)} = \prod_{c \in \text{object}} \text{objects} \in \text{reactant (reaction, role).objects (1)}
\]

role ∈ {e, g, i, s, tr(a), tr(r)}, (e: enzyme; g: gene; i: inhibitor; s: substrate; tr(a): transcriptional activator, tr(r): transcriptional repressor).

Subsequently, the flux of a metabolic pathway, \(\text{flux(P)}\), was calculated as the sum of intensities in reactions within this pathway deducted by the intensities of reactions going out into crosstalk pathways.

\[
\text{flux(P)} = \left[ \sum I_j \text{(reaction}_\epsilon\text{P, role)} / N(P) \right] - \text{flux(Crosstalk(P)) (3)}
\]

\(N(P)\): the number of reactions of the pathway P; \(\text{Crosstalk(P)}\): the crosstalk pathways related to the pathway P.

\[
\text{IM.Index[patient]} = \sum \text{flux(P)} / N(P) \text{ (Supplementary Information 1)}. 
\]

**Statistical Considerations**

The time interval for overall survival was calculated starting from the date of hospital admission until death from SARS-CoV-2 pneumonia or the date of the last follow-up. An event was considered death due to SARS-CoV-2 pneumonia. Mortality was determined via the vital status of each patient at the end of the study observation period. For data analysis continuous variables were reported as median (IQR) and categorical variables were shown as frequency or percentage. The least
absolute shrinkage and selection operator (LASSO) was used for multivariable selection (18). The area under curve (AUC) value was used to evaluate the accuracy of the vital status prediction. The Cox proportional hazards regression analysis was used to evaluate the prediction of a prognostic model for overall survival. Proportional hazards assumption for the Cox proportional hazards regression model was assessed via the Schoenfeld residuals test. The 95% confidence intervals (CIs) were estimated via 5,000 bootstraps replicates. Propensity score matching (PSM) was performed to adjust demographic factors (including age, sex, comorbidities), survival status and treatments. All statistical analyses were performed using R (version 3.6) and SAS (version 9.4). A \( p < 0.05 \) was considered as statistically significant.

**Role of Funding**

The funders were not involved in any activities of this study, aside from providing financing.

**RESULTS**

**Demographic and Clinical Features in the Elderly Cohort**

The elderly cohort (age ≥65 years old) consisted of 223 patients, which were admitted between Jan. and Mar. 2020 to four different Wuhan hospitals: 101 from TJH, 63 from WPH, 38 from WNH, and 21 from RHWU. As shown in Table 1, 132 (59.2%) patients died during hospitalization, 91 (40.8%) recovered and attained discharge criteria. The median age of this elderly cohort was 72.0 year (IQR 68.0–77.5). There was no significant age and body mass index (BMI) difference between both subgroups (survival vs. deceased). Gender was almost equally distributed (50.2% [M] vs. 49.8% [F]). Thirty-five (15.7%) patients were treated in an intensive care unit (ICU), and one of these patients was subsequently discharged. In 140 (62.8%) patients, symptoms of acute respiratory distress syndrome (ARDS) developed with 23 (25.3%) of these patients recovering. The majority of patients (74.4%) were affected by underlying diseases, hypertension (53.4%) being the most common (Table 1). The most common initial symptoms were fever (69.5%), cough (51.1%), and dyspnea (31.4%). The median body temperature on admission was 36.7°C (IQR 35.6–37.2), no difference of median temperature between both subgroups (survival vs. deceased) was seen. Similarly, both subgroups reported the same median interval (10 days) from symptom onset to hospital admission (Table 1). The hospitalization in the surviving subgroup was significantly longer than that of the deceased subgroup (20.0 days [IQR 15.0–25.0] vs. 8.0 days [IQR 5.0–13.0]). The majority of patients received antiviral treatments (lopinavir/ritonovir; 96%), antibiotics (86.1%), and corticosteroids (71.3%). Additionally, almost half of patients received interferon (47.1%) and immunoglobulin (48.0%) treatment. In this cohort, the most frequently applied oxygen therapies were UOC (84.8%) and NIMV (43.9%). All key laboratory findings of this cohort are listed in Table 1.

**Potential Survival Factors Associated With Vital Status for Elderly Patients With COVID-19**

The results of a univariate analysis showed that the odds of survival for elderly patients with COVID-19 were higher in patients having elevations in lymphocyte count, albumin, creatinine, and blood platelet count (Table 2). Among the recorded comorbidities only hypertension was significantly associated with survival (\( p = 0.042 \)), others such as diabetes, carcinoma, and coronary diseases did not influence survival in this cohort (Table 2). Drug treatments including antibiotics (OR: 10.16 [95% CI 3.73–27.69], \( p < 0.001 \)), corticosteroids (OR: 2.03 [95% CI 1.13–3.65], \( p = 0.018 \)) and immunoglobulin (OR: 2.43 [95% CI 1.4–4.21], \( p = 0.002 \)) negatively influenced survival in this cohort, whereas interferon’s therapy (OR: 0.29 [95% CI 0.17–0.51], \( p < 0.001 \)) showed a positive association with survival. Other potential factors were listed in Table 2. Using a multivariate analysis in this cohort (132 survivals vs. 91 deceased), the results showed that three significant survival factors were identified, including deceased D-Dimer, decreased IM.Index, decreased neutrophil-to-lymphocyte ratio (Table 2).

**Pathological Alteration From the Admission to Clinical Endpoint**

Laboratory markers regarding immunity, inflammation, metabolism, and other physiological functions were tracked from admission to the end point of clinical observation (Figure 2). Baseline counts of leukocytes and neutrophils increased continuously in deceased subgroup compared to the survival subgroup; whereas severe lymphopenia occurred in deceased subgroup. Levels of blood platelet count, calcium, and albumin were continuously reduced in the deceased subgroup (Figure 2). From 10 days on, the level of total protein significantly decreased in deceased than in survival subgroup. The level of urea and lactate dehydrogenase were moderately higher in deceased than in survival subgroup (Figure 2).

**Metabolic Alteration Between Deceased and Survival in COVID-19**

We hypothesized a significant difference in metabolic pathway utilization could exist between deceased and surviving subgroups. Thus, a genome-scale metabolic flux analysis was conducted for both subgroups. The results showed that fluxes from 12 metabolic pathways in the deceased patients were consistently and significantly higher than that of the surviving patients (Figure 3A). These changes were seen in the phenylalanine- (OR: 28.27 [95% CI 10.56–75.72], \( p < 0.001 \)), tyrosine- (25.81 [95% CI 9.8–67.99], \( p < 0.001 \)), glutathionie- (17.23 [95% CI 7.16–41.46], \( p < 0.001 \)), purine- (16.34 [95% CI 6.88–38.88], \( p < 0.001 \)), fatty acid- (15.61 [95% CI 6.66–36.6], \( p < 0.001 \)) -metabolic pathways, among others (Table 3). Similar differences were observed between the patients surviving after ARDS and those who did not (Figure 4A). Differences in metabolic flux was not observed between genders. The results of metabolic flux analysis also showed that the immune-related metabolic index
| Characteristics                              | Overall  | Survivor | Deceased | P-value |
|---------------------------------------------|----------|----------|----------|---------|
| Number of patients                          | 223      | 91 (40.8)| 132 (59.2)| ...     |
| Median age, years                           | 72.0 (68.0–77.5) | 70.0 (67.0–74.5) | 74 (69.0–80.0) | < 0.001 |
| Sex                                         | ...      | ...      | ...      | 0.077   |
| Male                                        | 112 (50.2)| 39 (42.9)| 73 (55.3)| ...     |
| Female                                      | 111 (49.8)| 52 (57.1)| 59 (44.7)| ...     |
| Body mass index (BMI)                       | 23.2 (20.0–24.9) | 23.3 (20.1–25.2) | 23.1 (20.0–24.8) | 0.751   |
| ICU care                                    | ...      | ...      | ...      | < 0.001 |
| Yes                                         | 35 (15.7)| 1 (1.1)  | 34 (25.8)| ...     |
| No                                          | 188 (84.3)| 90 (88.9)| 98 (74.2)| ...     |
| Smoking                                     | ...      | ...      | ...      | 0.682   |
| Yes                                         | 27 (12.1)| 12 (13.2)| 15 (11.4)| ...     |
| No                                          | 196 (87.9)| 79 (86.8)| 117 (88.6)| ...     |
| ARDS                                        | 140 (62.8)| 23 (25.3)| 117 (88.8)| ...     |
| IM Index                                    | 9.38 (9.06–9.78) | 9.14 (8.86–9.34) | 9.64 (9.30–10.00) | < 0.001 |
| Comorbidities                               | 166 (74.4)| 67 (73.6)| 99 (75.0)| 0.876   |
| Hypertension                                | 119 (53.4)| 41 (45.1)| 78 (59.1)| 0.042   |
| CVDs                                        | 33 (14.8)| 10 (11.0)| 25 (17.4)| 0.249   |
| Diabetics                                   | 52 (23.3)| 17 (18.7)| 35 (26.5)| 0.199   |
| Carcinoma                                   | 9 (4.0)  | 3 (6.6)  | 3 (2.3)  | 0.164   |
| Initial common symptoms                     | 213 (95.5)| 86 (94.5)| 127 (96.2)| 0.744   |
| Fever                                       | 155 (69.5)| 59 (64.8)| 96 (72.7)| 0.237   |
| Cough                                       | 114 (51.1)| 44 (48.4)| 70 (53.0)| 0.499   |
| Dyspnea                                     | 43 (19.3)| 15 (16.5)| 28 (21.2)| 0.395   |
| Admission body temperature, °C              | 36.7 (36.5–37.2) | 36.7 (36.5–37.2) | 36.7 (36.5–37.2) | 0.883   |
| Symptom onset to admission, days            | 10.0 (7.0–14.0) | 10.0 (7.0–14.0) | 10.0 (6.0–14.0) | 0.647   |
| Hospitalization, days                       | 13.0 (7.0–20.0) | 20.0 (15.0–25.0) | 8.0 (5.0–13.0) | < 0.001 |
| Systolic pressure, mm Hg                    | 131.0 (120.0–146.0) | 128.0 (120.5–141.0) | 133 (120.0–148.5) | 0.152   |
| Respiratory rate, breaths per min           | 22.0 (20.0–26.0) | 20.0 (20.0–25.0) | 22 (20.0–29.3) | 0.022   |
| Pulse rate, beats per min                   | 88.0 (80.0–100.5) | 84.0 (78.0–96.0) | 90 (80.0–103.0) | 0.003   |
| Antibiotics                                 | 192 (86.1)| 65 (71.4)| 127 (96.2)| < 0.001 |
| Antiviral treatment                         | 214 (96.0)| 65 (71.4)| 124 (93.9)| 0.086   |
| Corticosteroids                             | 159 (71.3)| 57 (62.6)| 102 (77.3)| 0.024   |
| Interferon atmortherapy                     | 105 (47.1)| 59 (64.8)| 46 (34.8)| < 0.001 |
| Immunoglobin                                | 107 (48.0)| 32 (35.2)| 75 (56.8)| 0.002   |
| Oxygen therapy                              | 213 (95.5)| 82 (90.1)| 131 (99.2)| 0.002   |
| UOC                                         | 189 (84.8)| 82 (90.1)| 107 (81.1)| 0.087   |
| HFNO                                        | 30 (13.5)| 20 (22.0)| 10 (7.6)| 0.003   |
| NIMV                                        | 98 (43.9)| 7 (7.7)| 91 (68.9)| < 0.001 |
| IMV                                         | 39 (17.5)| 1 (1.1)| 38 (28.8)| < 0.001 |
| ECMO                                        | 5 (2.2)  | 0| 5 (3.8)| 0.081   |

Laboratory findings

| WBC count, × 10^9/L | Overall | Survivor | Deceased | P-value |
|---------------------|---------|----------|----------|---------|
| <3.5                | 19 (8.5)| 9 (9.9)  | 10 (7.6) | ...     |

(Continued)
| Neutrophil count, $\times 10^9$/L | Overall | Survivor | Deceased | P-value |
|---------------------------------|---------|----------|----------|---------|
| $<1.1$                          | 76 (34.1) | 12 (13.2) | 64 (48.5) | ... |
| $1.1-6.3$                       | 107 (48.0) | 64 (70.3) | 43 (32.6) | ... |
| $>6.3$                          | 107 (48.0) | 22 (24.2) | 85 (64.4) | ... |
| Lymphocyte count, $\times 10^9$/L | ...    | ...      | ...      | 0.000 |
| $<0.5$                          | 76 (34.1) | 12 (13.2) | 64 (48.5) | ... |
| $0.5-1.8$                       | 9 (4.0) | 5 (5.5) | 4 (3.0) | ... |
| $>1.8$                          | 107 (48.0) | 22 (24.2) | 85 (64.4) | ... |
| APTT, s                         | ...    | ...      | ...      | 0.001 |
| $<29$                           | 18 (8.1) | 3 (3.3) | 15 (11.4) | ... |
| $29-42$                         | 155 (69.5) | 72 (79.1) | 83 (62.9) | ... |
| $>42$                           | 50 (22.4) | 16 (17.6) | 34 (25.8) | ... |
| PT, s                           | ...    | ...      | ...      | 0.001 |
| $\leq 14.5$                     | 139 (62.3) | 75 (82.4) | 64 (48.5) | ... |
| $>14.5$                         | 84 (37.7) | 16 (17.6) | 68 (51.5) | ... |
| D-D dimer, ug/ml FEU            | ...    | ...      | ...      | 0.001 |
| $<0.5$                          | 50 (22.4) | 39 (42.9) | 11 (8.3) | ... |
| $\geq 0.5$                      | 173 (77.6) | 52 (57.1) | 121 (91.7) | ... |
| ALT, U/L                        | ...    | ...      | ...      | 0.553 |
| $<33$ (female) or 41 (male)     | 156 (70.3) | 66 (72.5) | 90 (68.2) | ... |
| $\geq 33$ (female) or 41 (male) | 67 (30.0) | 25 (27.5) | 42 (31.8) | ... |
| AST, U/L                        | ...    | ...      | ...      | 0.001 |
| $<32$ (female) or 40 (male)     | 112 (50.2) | 61 (67.0) | 51 (38.6) | ... |
| $\geq 32$ (female) or 40 (male) | 111 (49.8) | 30 (33.0) | 81 (61.4) | ... |
| LDH, U/L                        | ...    | ...      | ...      | 0.001 |
| $\leq 214$ (female) or 225 (male) | 25 (11.2) | 20 (22.0) | 5 (3.8) | ... |
| $>214$ (female) or 225 (male)   | 198 (88.8) | 71 (78.0) | 127 (96.2) | ... |
| ALP, U/L                        | ...    | ...      | ...      | 0.001 |
| $<35$ (female) or 40 (male)     | 12 (5.4) | 7 (7.7) | 5 (3.8) | ... |
| $35-105$ (female) or 40–130 (male) | 185 (83.0) | 83 (91.2) | 102 (77.3) | ... |
| $>105$ (female) or 130 (male)   | 26 (11.7) | 1 (1.1) | 25 (18.9) | ... |
| $\gamma$-GT, U/L                | ...    | ...      | ...      | 0.224 |
| $<6$ (female) or 10 (male)      | 2 (0.9) | 2 (2.2) | 0 | ... |
| $6-42$ (female) or 10–71 (male) | 170 (76.2) | 70 (76.9) | 100 (75.8) | ... |
| $>42$ (female) or 71 (male)     | 51 (22.9) | 19 (20.9) | 32 (24.2) | ... |
| Urea, mmol/L                    | ...    | ...      | ...      | 0.001 |
| $<2.6$ (female) or 3.6 (male)   | 10 (4.5) | 5 (5.5) | 5 (3.8) | ... |
| $2.6-7.5$ (female) or 3.6–9.5 (male) | 130 (58.3) | 72 (79.1) | 58 (43.9) | ... |
| $>7.5$ (female) or 9.5 (male)   | 83 (37.2) | 14 (15.4) | 69 (52.3) | ... |
| Albumin, g/L                    | ...    | ...      | ...      | 0.001 |
| $<35$                           | 152 (68.2) | 48 (52.7) | 104 (78.8) | ... |
| $\geq 35$                       | 71 (31.8) | 43 (47.3) | 24 (18.2) | ... |
TABLE 1 | Continued

| Overall | Survivor | Deceased | P-value |
|---------|----------|----------|---------|
| Total cholesterol, mmol/L | ... | ... | ... | 1.000 |
| <5.18 | 212 (95.1) | 87 (95.6) | 125 (94.7) | ... |
| ≥5.18 | 11 (4.9) | 4 (4.4) | 7 (5.3) | ... |
| Total bilirubin, µmol/L | ... | ... | ... | 0.009 |
| <21 (female) or 26 (male) | 198 (88.8) | 87 (95.6) | 111 (84.1) | ... |
| ≥21 (female) or 26 (male) | 25 (11.2) | 4 (4.4) | 21 (15.9) | ... |
| hs-CRP, mg/L | ... | ... | ... | < 0.001 |
| <10.0 | 26 (11.7) | 21 (23.1) | 5 (3.8) | ... |
| ≥10.0 | 197 (88.3) | 70 (76.9) | 127 (96.2) | ... |

Data are median (IQR), or n (%). ICU, Intensive care unit; ARDS, Acute respiratory distress syndrome; UOC, Usual oxygen care, including standard nasal catheter and facemask inhalation; HFNO, High-flow nasal cannula oxygen; (N)IMV, (Non-) Invasive mechanical ventilation; ECMO, Extracorporeal membrane oxygenation; WBC, White blood cell; PLT, Blood platelet; APTT, Activated partial thromboplastin time; PT, Prothrombin time; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; LDH, Lactate dehydrogenase; ALP, Alkaline phosphatase; γ-GT, gamma-Glutamyl transpeptidase; hs-CRP, high-sensitivity C-reactive protein.

(IM.Index) was significantly lower in the surviving subgroup than that of the deceased subgroup (9.14 [95% CI 8.86–9.34] vs. 9.64 [95% 9.3–10.0]; Table 1, Figure 3C). Further, circulating levels of three cytokines (IL6, IL8, and IL10) were significantly increased in the deceased subgroup (Figure 3B).

**Algorithm for Survival Prediction in Elderly Patients With COVID-19**

Given the high mortality rate of elderly patients, an algorithm (AlgSurv) to predict survival was developed based on the weight of the three significant predictors (Table 2). The AlgSurv yielded an AUC of 0.863 (95% CI 0.817–0.909) in successfully predicting survival in this cohort as well as a Harrell’s c-index of 0.769 (95% CI 0.73–0.808) for overall survival. In this elderly cohort, the AlgSurv was able to define a high-risk subgroup with a significantly lower prognosis (hazard ratio: 5.85 [95% CI 3.76–9.08]) vs. a low-risk subgroup with a high probability of survival (Figure 4B). The predicted 30-days survival rates of the high- and low-risk subgroups in this cohort is illustrated in Figure 4C (cutoff ≥ 10⁶ and <10⁶).

**DISCUSSIONS**

Elderly patients infected with COVID-19 have an increased risk of mortality which can be seen by the death rate in this multi-center study being 59.2%. In this cohort of patients, 62.8% developed acute respiratory distress syndrome (ARDS) with a total of 25.3% patients recovering. Underlying comorbidities were assessed to determine any association with mortality. Among them, hypertension was commonest comorbidity (54.3%) and was the only factor significantly associated with survival. Other identifiable survival factors of COVID-19 infection in this elderly cohort were use of interferon therapy, reduced activity reduction of metabolic pathways and specific biochemical markers trends (i.e., decreased D dimer, decreased IM index, decreased neutrophil to lymphocyte ratio). Based on these factors, an algorithm AlgSurv was developed, which yielded an AUC of 0.863 for predicting to outcome and C-index of 0.769 for overall survival, respectively.

The complicated virus/host interactions involved in the pathogenesis and outcome of SARS-CoV-2 remain under investigation. It was hypothesized that like other coronaviruses SARS-CoV-2 may evolve to alter metabolic pathways in its host to meet a drastically increasing demand of resource for replication and expansion (19, 20). In this study, a system-level metabolic flux analysis was performed to assess changes in metabolic pathways that were characteristic for older patients surviving the infection vs. those that did not. The fluxes of 12 metabolic pathways were consistently lower in surviving vs. the deceased subgroup. All of these metabolic pathways were involved with energy and nutrient metabolism such as glucose (21), fatty acid (22) and nucleic acid (23). This finding provides important evidence that host metabolism may play an important role in the general pathogenesis of COVID-19.

As the virus replicates, large amounts of energy and nutrients are needed and obtained from the metabolism of the host cells (24). In cellular metabolism, pyruvate metabolism connects ATP production from the citric acid cycle with oxidative phosphorylation pathways and many biosynthetic pathways (25). Moreover, this pathway was recently found to be a predictor of outcome follow a H7N9 virus infection (26). In our cohort, the flux of fatty acid metabolism was significantly increased in the deceased vs. surviving subgroup. Its upregulation could indicate an enhanced virus replication that parallels deterioration of host health. Of note, purine release and metabolism has a high impact on inflammatory responses relating to cytokine signaling (27). The enhanced activity of purine metabolism in the deceased subgroup may indicate an overly strong inflammatory response at the system level, as evidenced by the hyper-elevated cytokine production in this subgroup. Such a “cytokine storm” may thereby decrease the probability for survival.

Phenylalanine metabolism was observed to be highly upregulated in the deceased subgroup. These findings indicate that SARS-CoV-2 may function in a similar way as the respiratory syncytial virus (28) in utilizing the phenylalanine residue for
TABLE 2 | Survival/Risk factors associated with mortality in age-specific patient cohort infected with COVID-19.

| Demographic and clinical characteristics | AOR (95% CI) | Wald’s P-value |
|-----------------------------------------|-------------|----------------|
| Hypertension: 1 vs. 0                   | 1.76 (1.03, 3.02) | 0.040 |
| Respiratory rate, breaths per min       | 1.08 (1.02, 1.13) | 0.006 |
| Pulse rate, beats per min               | 1.03 (1.01, 1.05) | 0.001 |
| Treatments                              |             |                |
| Antibiotics: 1 vs. 0                    | 10.16 (3.73, 27.69) < 0.001 |
| Corticosteroids: 1 vs. 0                | 2.03 (1.13, 3.65) < 0.018 |
| Interferon atmotherapy: 1 vs. 0        | 0.29 (0.17, 0.51) < 0.001 |
| Immunoglobulin: 1 vs. 0                 | 2.43 (1.4, 4.21) < 0.001 |
| Non-invasive mechanical ventilation (NIMV): 1 vs 0 | 27.3 (11.6, 64.26) < 0.001 |
| Invasive mechanical ventilation (IMV): 1 vs. 0 | 36.77 (4.94, 273.53) < 0.001 |

| Immune components                       |             |                |
| White blood cell (WBC) count, x 10^9/L  | 1.23 (1.14, 1.34) < 0.001 |
| Neutrophil count, x 10^9/L              | 1.28 (1.17, 1.41) < 0.001 |
| Lymphocyte count, x 10^9/L              | 0.2 (0.1, 0.41) < 0.011 |
| Neutrophil ratio                        | 1.08 (1.03, 1.21) < 0.001 |
| Lymphocyte ratio                        | 0.12 (0.08, 0.23) < 0.001 |
| Neutrophil/lymphocyte ratio             | 1.12 (1.08, 1.17) < 0.001 |
| IM.Index                                 | 13.82 (6.19, 30.83) < 0.001 |

| Other laboratory findings                |             |                |
| Alanine transaminase (ALT), U/L         | 1.01 (1.01, 1.03) | 0.049 |
| Aspartate aminotransferase (AST), U/L   | 1.04 (1.02, 1.06) < 0.001 |
| Alkaline phosphatase (ALP), U/L         | 1.02 (1.01, 1.04) < 0.001 |
| Lactate dehydrogenase (LDH), U/L        | 1.0063 (1.0042, 1.0085) < 0.001 |
| gamma-Glutamyl transpeptidase (γ-GT), U/L | 1.007 (1.0002, 1.0139) | 0.044 |
| Total bilirubin, µmol/L                 | 1.11 (1.06, 1.17) < 0.001 |
| Albumin, g/L                            | 0.83 (0.77, 0.89) < 0.001 |
| Creatine kinase (CK), U/L               | 1.0078 (1.0009, 1.0147) | 0.026 |
| Urea, mmol/L                            | 1.11 (1.06, 1.17) < 0.001 |
| Uric acid, µmol/L                       | 1.0025 (1.0005, 1.0045) | 0.013 |
| K+, mmol/L                              | 1.63 (1.08, 2.46) | 0.020 |
| Na+, mmol/L                             | 1.06 (1.01, 1.11) | 0.025 |
| CI -, mmol/L                            | 1.05 (1.01, 1.10) | 0.039 |
| P, mmol/L                               | 9.36 (2.26, 38.82) | 0.002 |
| Mg2+, mmol/L                            | 17.12 (3.1, 94.6) | 0.001 |
| high-sensitivity C-reactive protein (hs-CRP), mg/L | 1.02 (1.01, 1.03) < 0.001 |
| Creatinine, umol/L                      | 0.98 (0.97, 0.99) < 0.001 |
| Blood platelet (PLT) count, x 10^9/L     | 0.9928 (0.9893, 0.9963) < 0.001 |
| Prothrombin time (PT), s                | 1.24 (1.08, 1.42) | 0.003 |
| D-D dimer, µg/mL FEU                    | 1.21 (1.12, 1.32) < 0.001 |

| Multivariate analysis                   | AOR (95% CI) | Wald’s P-value |
|-----------------------------------------|-------------|----------------|
| Number of events/patients (%)           | 132/223 (59.2%) ... |
| D-D dimer, µg/mL FEU                    | 1.13 (1.04–1.22) | 0.005 |
| IM.Index                                 | 6.42 (2.66–15.48) < 0.001 |

(Continued)
Mei et al. Survival Factors and Metabolic Pathogenesis in Elderly COVID-19 Patients

FIGURE 2 | Pathological alternation from the admission to clinical endpoint between deceased and survival subgroups. Timeline charts illustrate the laboratory parameters (A: Leukocyte count, B: Neutrophil count, C: Lymphocyte count, D: Blood platelet count, E: Urea, F: Calcium, G: Albumin, H: Total Protein, I: Lactate dehydrogenase) in elderly COVID-19 patients during defined period of clinical observation. Survival and deceased groups are symbolized with dark orange and blue color.

cohort. Although this finding is consistent with outcomes of two recent clinical trials (33, 34), future large-cohort studies are warranted to address the efficacy and side-effect of interferon based treatment on COVID-19 patients with a severe and critical illness disease course. The majority of patients (74.4%) in this cohort had underlying comorbidities. Although hypertension ($p = 0.042$) was slightly related to mortality, diabetes, carcinoma, and coronary heart diseases were not. This contradicts many recent studies that reported a significant association of underlying diseases with the mortality of patients with COVID-19 (35–37). The reason for this discrepancy could be that advanced age could be a risk factor associated with the mortality of COVID-19, and comorbidity itself could only be an independent factor associated with advanced age. For instance, elderly individuals are more likely to have chronic kidney disease and diabetes (38, 39). On the one hand, such diseases lowers the person’s immunity, and when treated with angiotensin converting enzyme 2 (ACE-2) inhibitors or angiotensin-receptor blockers (ARBs) that upregulate ACE-2 receptor (20), could enable a more aggressive SARS-CoV-2 virus entry. In our age-specific cohort study, the influence of advanced age was drastically reduced and therefore the age related dependency of comorbidity was compromised, leading to its dissociation with observed mortality.

Of note, no difference in the time interval from symptom onset to hospital admission was observed between survival and deceased subgroups. Similarly, no difference in body temperature on admission between both subgroups was observed. These results indicated guidelines recommending hospital admission within 10 days and body temperature between 36.5 and 37.2 on admission may be unrelated to the survival of elderly patients with COVID-19.

This study has several strengths. First of all, it provides a comprehensive scientific discussion of COVID-19 that are clinically important and relevant to COVID-19 during this pandemic setting. To our knowledge, it is the first paper focusing on metabolic pathogenesis in the elderly population who are amongst the highest risk patients for severe complications of COVID-19. Furthermore, there is limited literature of this specific population given the novelty of the illness. Therefore, early recognition of at-risk elderly individuals, stratifying their risk profiles (i.e., comorbidities) and developing appropriate drug therapy to be prescribed in a timely matter is critical to reduce the mortality of COVID-19. Secondly, this paper assists a possible understanding of COVID-19 pathophysiology and explores how the deregulation of metabolic pathways can serve as a potential target for further drug development and may assist in future studies. Finally, it aims to identify important survival factors,
FIGURE 3 | Comparison of metabolic flux and IM.Index. (A) Difference of metabolic flux in 12 metabolic pathways between survival and deceased subgroup in the elderly cohort (≥ 65 years old). (B) Differences of IM.Index, IL6, IL8, and IL10 in survival vs. deceased subgroups, and the clinical differentiation of IM.Index in the cohort. (C) Visualization of metabolic flux in survival vs. deceased subgroup (a more comprehensive view in Supplementary Figure 1). ***P = 0.001, **P = 0.01, *P = 0.05.

TABLE 3 | Odds ratio of metabolic pathway in age-specific patient cohort infected with COVID-19.

| Pathway survival analysis | AOR (95%CI) | Wald's P-value |
|---------------------------|-------------|----------------|
| Metabolic pathway         |             |                |
| Phenylalanine metabolism  | 28.27 (10.56, 75.72) | < 0.001        |
| Arginine and proline      | 27.68 (10.38, 73.84)  | < 0.001        |
| Tyrosine metabolism       | 25.81 (9.8, 67.99)    | < 0.001        |
| Alanine aspartate and glutamate metabolism | 25.72 (9.77, 67.69) | < 0.001        |
| Glutathione metabolism    | 17.23 (7.16, 41.48)   | < 0.001        |
| Cysteine and methionine metabolism | 16.78 (7.14, 39.41) | < 0.001        |
| Folate biosynthesis       | 16.38 (6.9, 38.85)    | < 0.001        |
| Purine metabolism         | 16.34 (6.88, 38.81)   | < 0.001        |
| Steroid biosynthesis      | 15.62 (6.66, 36.62)   | < 0.001        |
| Retinol metabolism        | 15.62 (6.66, 36.61)   | < 0.001        |
| Fatty acid metabolism     | 15.61 (6.66, 36.6)    | < 0.001        |
| Pyruvate metabolism       | 12.86 (5.85, 28.28)   | < 0.001        |
| Propanoate metabolism     | 12.82 (5.84, 28.15)   | < 0.001        |

AOR, Adjusted odds ratio; CI, Confidence interval.

such as prescription of interferon atmotherapy treatment, which has the potential for being an effective novel therapy.

This study has several limitations. First, the median age of this cohort is 72 years old, which may not reflect the whole elderly population. It is a small population study, which could be underpowered. Secondly, we focused only on elderly patients (≥65) infected with COVID-19 in Wuhan, China, which may not be representative of the whole population in China. The case-fatality rate in this study was therefore the highest among all reported studies to the present, and therefore likely much higher than the actual mortality of COVID-19 worldwide. Thirdly, the developed AlgSurv needs to be further validated with a large international cohort. Further, the treatment benefit of interferon atmotherapy was investigated in this cohort through PSM. However, PSM is not a substitute of a randomized study (40) and this finding therefore needs to be verified in a randomized control trial. Finally, we acknowledge that metabolic pathway’s activity cannot actually assist the clinician in real-time, however, better understanding of this metabolic pathway can potentially assists in development of a target therapy for this pandemic disease. The discovered metabolic mechanisms related to the pathogenesis of
COVID-19 were derived from this age-specific cohort. Follow-up studies will need to verify this issue in other cohorts. IM.Index was initially developed analyzing RNA sequencing data (under review). Under the emergency situation of this pandemic, this score index was applied to the analysis of the laboratory blood values of COVID-19 patients. Therefore, the impact of this index score applied here may different from that when analyzing RNA sequencing data.

CONCLUSION

Our study investigated an age-specific elderly patient cohort suffering from COVID-19. Although a high mortality has been reported for these patients, several potential survival factors were identified in this study, such as interferon atmotherapy and reduced metabolic pathway activities. These survival factors may be relevant to improving outcomes among elderly patients with
COVID-19. The developed AlgSurv can be applied for clinical risk stratification. Dysregulation of different metabolic pathways revealed in this study suggest potential new therapeutic targets against COVID-19.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

This study was approved by the institutional ethics board of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology (No. IRBID-TJ-C 20200107). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

QM, AW, and JL: wrote the manuscript. JL and CK: statistical analysis. YY, ML, FW, and KM: data collection. LW, PW, QM, AW, and JL: wrote the manuscript. JL and CK: statistical

REFERENCES

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33. doi: 10.1056/NEJMoa2001017
2. WHO Reports. Available online at: https://covid19.who.int/ (accessed October 8, 2020).
3. Richardson S, Hirsch J, Narasimhan M, Crawford J, McGinn T, Davidson K, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. (2020) 323:2052–9. doi: 10.1001/jama.2020.6773
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
5. Kobayashi KI, Kaki T, Mizuno S, Kubo K, Komiya N, Otsu S, et al. Clinical characteristics of patients with coronavirus disease 2019 in Japan: a single-center case series. J Infect Dis. (2020) 222:194–7. doi: 10.1093/infdis/jiaa244
6. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York city: a prospective cohort study. Lancet. (2020) 395:1763–70. doi: 10.1016/S0140-6736(20)31189-2
7. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. (2020) 382:1708–20. doi: 10.1056/NEJMoa2002322
8. Goyal P, Choi J, Pinheiro LC, Schenk E, Chen R, Jabri A, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. (2020) 382:2372–4. doi: 10.1056/NEJMc2001419
9. Wu Z, cropped

FUNDING

This study was funded by the SGC’s Rapid Response Funding for Bilateral Collaborative Emergence COVID-19 Project between China and Germany (No. C-0065), the Public Health and Family Planning Research Project of Hubei Province (No. WJ2019M128), Natural Science Foundation of Hubei Province (No. 2019CFB449), and General program of National Natural Science Foundation of China (No. 81372664). The funders were not involved in any activities of this study, aside from providing financing.

ACKNOWLEDGMENTS

We thank all patients and their families involved in this study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2020.595503/full#supplementary-material

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY Figure 1 | Estimation of metabolic flux in a large-scale molecular model MCPM.

SUPPLEMENTARY Information 1 | Algorithm for utilization of laboratory measurements for the generation of IM.Index.

SUPPLEMENTARY Information 2 | Flux difference of 46 pathways within MCPM model.

10. Xu J, Kang Y, Park SK, Yoon Y, Bai SJ, Jin YD, et al. Nasality changes with age in normal Korean-speaking adults. Clin Exp Otorhinolaryngol. (2019) 12:95–9. doi: 10.21053/ceo.2018.00717
11. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. (2007) 120:435–46. doi: 10.1111/j.1365-2567.2007.02555.x
12. Xia S, Zhang X, Zheng S, Khanabdali R, Kalionis B, Wu J, et al. An update on inflamm-aging: mechanisms, prevention, and treatment. J Immunol Res. (2016) 2016:8426874. doi: 10.1155/2016/8426874
13. Kelly PN. Metabolism as a driver of immune response. Science. (2019) 363:365–9. doi: 10.1126/science.363.6423.137-
14. Maasila P, Holsti LR, Halme M, Kivisaari L, Cantell K, Mattson K. Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer. Int J Radiat Oncol. (1992) 23:863–8. doi: 10.1016/0360-3016(92)90660-a
15. Chen L, Shi M, Deng Q, Liu W, Li Q, Ye P, et al. A multi-center randomized prospective study on the treatment of infant bronchiolitis with interferon α1b nebulization. PLoS ONE. (2020) 15:e0228391. doi: 10.1371/journal.pone.0228391
19. Wu Q, Zhou L, Sun X, Yan Z, Hu C, Wu J, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. (2017) 7:9110. doi: 10.1038/s41598-017-09366-z

20. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. (2020) 17:259–68. doi: 10.1038/s41569-020-0360-5

21. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. (2011) 27:441–64. doi: 10.1146/annurev-cellbio-092910-154237

22. Huber K, Hofer DC, Trefely S, Pelzmann H, Maddreiter-Sokolowski C, Dutta-Mare M, et al. N-acetylaspartate pathway is nutrient responsive and coordinates lipid and energy metabolism in brown adipocytes. Biochim Biophys Acta Mol Cell Res. (2019) 1866:337–48. doi: 10.1016/j.bbamcr.2018.08.017

23. Lane AN, Fan TWM. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. (2015) 43:2466–85. doi: 10.1093/nar/gkv047

24. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Cell Mol Life Sci. (2019) 76:1227–47. doi: 10.1007/s00018-018-0118-9

25. Gray LR, Tompkins SC, Taylor EB. Regulation of pyruvate metabolism and human disease. Cell Mol Life Sci. (2014) 71:2577–604. doi: 10.1007/s00018-013-1539-2

26. Sun X, Song L, Feng S, Li L, Yu H, Wang X, et al. Fatty acid metabolism is responsive to COVID-19: an open-label, randomised, phase 2 trial. Lancet. (2020) 395:1695–704. doi: 10.1016/S0140-6736(20)31042-4

27. Linden J, Koch-Nolte F, Dahl G. Purine release, metabolism, and signaling in the inflammatory response. Annu Rev Immunol. (2019) 37:325–47. doi: 10.1146/annurev-immunol-051116-052406

28. Shaikh FY, Cox RG, Liffand AW, Hotard AL, Williams JV, Moore ML, et al. A critical phenylalanine residue in the respiratory syncytial virus fusion protein cytoplasmic tail mediates assembly of internal viral proteins into viral filaments and particles. MBio. (2012) 3:e00270-11. doi: 10.1128/mBio.00270-11

29. Buck MD, O’Sullivan D, Pearce EL. T cell metabolism drives immunity to cell metabolism drives immunity. J Exp Med. (2015) 212:1345–60. doi: 10.1084/jem.20151159

30. Blažih I, Coulombe E, Vincent E, Dupuy F, Galicia-Vazquez G, Yurchenko E, et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity. (2015) 42:41–54. doi: 10.1016/j.immuni.2014.12.030

31. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. (2020) 370:ab4570. doi: 10.1126/science.abd4570

32. van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. (2020) 324:663–73 doi: 10.1001/jama.2020.13719

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Mei, Wang, Bryant, Yang, Li, Wang, Du, Karts, Wu, Ma, Wu, Chen, Luo, Li, Hu, Yuan and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.